Kenvue Inc. (NYSE:KVUE) Short Interest Down 20.5% in January

Kenvue Inc. (NYSE:KVUE - Get Free Report) was the recipient of a large decrease in short interest in January. As of January 31st, there was short interest totalling 26,560,000 shares, a decrease of 20.5% from the January 15th total of 33,420,000 shares. Based on an average daily trading volume, of 12,960,000 shares, the days-to-cover ratio is currently 2.0 days. Approximately 1.4% of the shares of the company are sold short.

Institutional Investors Weigh In On Kenvue

Several large investors have recently added to or reduced their stakes in KVUE. Norges Bank acquired a new stake in Kenvue during the fourth quarter worth approximately $521,348,000. Starboard Value LP bought a new position in Kenvue in the fourth quarter worth approximately $467,864,000. State Street Corp boosted its holdings in Kenvue by 16.8% in the third quarter. State Street Corp now owns 127,213,940 shares of the company's stock worth $2,942,458,000 after acquiring an additional 18,283,473 shares in the last quarter. Franklin Resources Inc. boosted its holdings in Kenvue by 61.5% in the fourth quarter. Franklin Resources Inc. now owns 42,719,377 shares of the company's stock worth $912,059,000 after acquiring an additional 16,269,721 shares in the last quarter. Finally, Massachusetts Financial Services Co. MA boosted its holdings in Kenvue by 12.3% in the fourth quarter. Massachusetts Financial Services Co. MA now owns 97,661,344 shares of the company's stock worth $2,085,070,000 after acquiring an additional 10,682,003 shares in the last quarter. Institutional investors and hedge funds own 97.64% of the company's stock.

Kenvue Trading Up 2.3 %

Shares of KVUE stock traded up $0.49 on Monday, hitting $21.94. The company had a trading volume of 27,015,716 shares, compared to its average volume of 13,018,513. The firm has a market cap of $42.07 billion, a P/E ratio of 41.40, a P/E/G ratio of 2.16 and a beta of 1.45. The stock's 50-day moving average is $21.30 and its two-hundred day moving average is $22.12. The company has a debt-to-equity ratio of 0.66, a quick ratio of 0.69 and a current ratio of 1.00. Kenvue has a twelve month low of $17.67 and a twelve month high of $24.46.

Kenvue (NYSE:KVUE - Get Free Report) last released its earnings results on Thursday, February 6th. The company reported $0.26 EPS for the quarter, hitting the consensus estimate of $0.26. Kenvue had a return on equity of 20.97% and a net margin of 6.66%. On average, equities research analysts anticipate that Kenvue will post 1.05 earnings per share for the current fiscal year.

Kenvue Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, February 26th. Investors of record on Wednesday, February 12th will be paid a dividend of $0.205 per share. The ex-dividend date is Wednesday, February 12th. This represents a $0.82 annualized dividend and a yield of 3.74%. Kenvue's dividend payout ratio is currently 154.72%.

Analyst Upgrades and Downgrades

A number of research analysts have commented on the company. Canaccord Genuity Group decreased their price objective on Kenvue from $27.00 to $24.00 and set a "buy" rating on the stock in a report on Friday, February 7th. Barclays dropped their price objective on Kenvue from $23.00 to $21.00 and set an "equal weight" rating for the company in a research report on Friday, January 17th. Deutsche Bank Aktiengesellschaft downgraded Kenvue from a "buy" rating to a "hold" rating and dropped their price objective for the stock from $25.00 to $24.00 in a research report on Thursday, December 12th. UBS Group dropped their target price on Kenvue from $23.00 to $21.00 and set a "neutral" rating for the company in a research report on Friday, February 7th. Finally, Royal Bank of Canada reiterated a "sector perform" rating and issued a $24.00 target price on shares of Kenvue in a research report on Monday, February 3rd. One analyst has rated the stock with a sell rating, eight have given a hold rating and five have given a buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Hold" and a consensus price target of $23.00.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.